Gerritse, S. L.
109  Ergebnisse:
Personensuche X
?
 
?
2

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for c..:

van Helden, E. J. ; Elias, S. G. ; Gerritse, S. L....
European Journal of Nuclear Medicine and Molecular Imaging.  47 (2020)  10 - p. 2481-2481 , 2020
 
?
3

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monoth..:

van Helden, E. J. ; Elias, S. G. ; Gerritse, S. L....
European Journal of Nuclear Medicine and Molecular Imaging.  47 (2019)  4 - p. 849-859 , 2019
 
?
 
?
 
?
6

Correction to:[89Zr]Zr-cetuximab PET/CT as biomarker for ce..:

van Helden, E. J ; Elias, S. G ; Gerritse, S. L...
van Helden , E J , Elias , S G , Gerritse , S L , van Es , S C , Boon , E , Huisman , M C , van Grieken , N C T , Dekker , H , van Dongen , G A M S , Vugts , D J , Boellaard , R , van Herpen , C M L , de Vries , E G E , Oyen , W J G , Brouwers , A H , Verheul , H M W , Hoekstra , O S & der Houven van Oordt , C W M V 2020 , ' Correction to : [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 4, (849-859), 10.1007/s00259-019-04555-6) ' , European Journal of Nuclear Medicine and Molecular Imaging , vol. 47 , no. 10 , pp. 2481 . https://doi.org/10.1007/s00259-020-04908-6.  , 2020
 
?
7

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for c..:

van Helden, E. J ; Elias, S. G ; Gerritse, S. L...
https://research.rug.nl/en/publications/da94b5d8-8ca8-4c52-9158-c5c276ad65c6.  , 2020
 
?
8

Tumor drug exposure is positively correlated with an improv..:

Gerritse, S ; ter Heine, R ; Labots, M...
Gerritse , S , ter Heine , R , Labots , M , van den Hombergh , E , Dekker , H , Lehutová , D , Rudek , M , van Erp , N & Verheul , H 2020 , ' Tumor drug exposure is positively correlated with an improved outcome, in patients with advanced solid tumors, upon treatment with a high dose intermittent sunitinib regimen ' , European Journal of Cancer , vol. 138 , pp. S19 . https://doi.org/10.1016/S0959-8049(20)31114-X.  , 2020
 
?
9

[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monot..:

van Helden, E. J ; Elias, S. G ; Gerritse, S. L...
https://research.rug.nl/en/publications/22be926c-b15c-4a15-962e-99fa9cc8afa1.  , 2020
 
?
 
?
11

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monoth..:

van Helden, E. J ; Elias, S. G ; Gerritse, S. L...
van Helden , E J , Elias , S G , Gerritse , S L , van Es , S C , Boon , E , Huisman , M C , van Grieken , N C T , Dekker , H , van Dongen , G A M S , Vugts , D J , Boellaard , R , van Herpen , C M L , de Vries , E G E , Oyen , W J G , Brouwers , A H , Verheul , H M W , Hoekstra , O S & Menke-van der Houven van Oordt , C W 2020 , ' [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer ' , European Journal of Nuclear Medicine and Molecular Imaging , vol. 47 , no. 4 , pp. 849-859 . https://doi.org/10.1007/s00259-019-04555-6.  , 2020
 
?
14

Decalcification of Breast Cancer Bone Metastases With EDTA ..:

van Es, SC ; van der Vegt, B ; Bensch, F...
van Es , SC , van der Vegt , B , Bensch , F , Gerritse , S , van Heiden , EJ , Boon , E , Angus , L , Overbosch , J , van Oordt , C , Verheul , HM , van Herpen , CM , Jager , A , Oosting , SF , Vries , EG & Schroder , CP 2019 , ' Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results ' , American Journal of Surgical Pathology , vol. 43 , no. 10 , pp. 1355-1360 . https://doi.org/10.1097/pas.0000000000001321.  , 2019
 
?
 
1-15